Millipore Sigma Vibrant Logo

119136 Adenosine A1 Receptor Agonist II, CCPA - CAS 37739-05-2 - Calbiochem

119136
Voir les Prix & la Disponibilité

Aperçu

Replacement Information

Prix & Disponibilité

Référence DisponibilitéConditionnement Qté Prix Quantité
119136-10MG
Récupération des données relatives à la disponibilité...
Disponibilité limitéeDisponibilité limitée
En stock 
Interrompu(e)
Disponible en quantités limitées
Disponibilité à confirmer
    Pour le restant : Nous vous tiendrons informé
      Pour le restant : Nous vous tiendrons informé
      Nous vous tiendrons informé
      Contacter le Service Clients
      Contact Customer Service

      Flacon en verre 10 mg
      Prix en cours de récupération
      Le prix n'a pas pu être récupéré
      La quantité minimale doit être un multiple de
      Maximum Quantity is
      À la validation de la commande Plus d'informations
      Vous avez sauvegardé ()
       
      Demander le prix
      Description
      OverviewAn adenosine analog that acts as a selective, high affinity agonist for Adenosine A1 receptor (A1R) (Ki = 800 pM; 2.3 µM, 18.8 µM, and 42 nM for human A1, A2A, A2B, A3 respectively). Shown to be centrally active following systemic administration and exhibits anti-convulsive effects. Also reported to inhibit adenylate cyclase activity in rat fat cell membrane (IC50 = 33 nM). Diminishes respiratory rhythm, reduces heart rate, and enhances the activity of KATP channels. Reduces norepinephrine release by about 50% in untreated and pertussis toxin treated hearts.
      Catalogue Number119136
      Brand Family Calbiochem®
      Synonyms(2R,3R,4S,5R)-2-(2-chloro-6-(cyclopentylamino)-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol, 2-Chloro-N6-cyclopentyladenosine
      References
      ReferencesBurgdorf, C. et al. 2005. J Cardiovasc Pharmacol. 45, 1.
      Klotz, K. N., et al. 2000. Naunyn Schmiedebergs Arch Pharmacol. 362, 382.
      Mironov, S., et al. 1990. J Neurophysiol. 81, 1.
      Monopoli, A., et al. 1994.Arzneimittelforschung. 44, 1305.
      Concas, A., et al. 1993. J Pharmacol Exp Ther. 267, 844.
      Lohse, M. J., et al. 1988. Nauryn Schmiedebergs Arch Pharmacol. 337, 687.
      Coffin, V. L., et al. 1987. J Pharmacol Exp Ther. 241, 76.
      Product Information
      CAS number37739-05-2
      FormWhite solid
      Hill FormulaC₁₅H₂₀ClN₅O₄
      Chemical formulaC₁₅H₂₀ClN₅O₄
      ReversibleY
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Primary TargetA1
      Primary Target K<sub>i</sub>2.3 nM
      Purity≥99% by HPLC
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Shipped at Ambient Temperature or with Blue Ice or with Dry Ice
      Toxicity Standard Handling
      Storage +2°C to +8°C
      Protect from Light Protect from light
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications

      Documentation

      Adenosine A1 Receptor Agonist II, CCPA - CAS 37739-05-2 - Calbiochem FDS

      Titre

      Fiche de données de sécurité des matériaux (FDS) 

      Références bibliographiques

      Aperçu de la référence bibliographique
      Burgdorf, C. et al. 2005. J Cardiovasc Pharmacol. 45, 1.
      Klotz, K. N., et al. 2000. Naunyn Schmiedebergs Arch Pharmacol. 362, 382.
      Mironov, S., et al. 1990. J Neurophysiol. 81, 1.
      Monopoli, A., et al. 1994.Arzneimittelforschung. 44, 1305.
      Concas, A., et al. 1993. J Pharmacol Exp Ther. 267, 844.
      Lohse, M. J., et al. 1988. Nauryn Schmiedebergs Arch Pharmacol. 337, 687.
      Coffin, V. L., et al. 1987. J Pharmacol Exp Ther. 241, 76.
      Fiche technique

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision28-March-2013 JSW
      Synonyms(2R,3R,4S,5R)-2-(2-chloro-6-(cyclopentylamino)-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol, 2-Chloro-N6-cyclopentyladenosine
      DescriptionAn adenosine analog that acts as a selective, high affinity agonist for Adenosine A1 receptor (A1R) (Ki = 800 pM; 2.3 µM, 18.8 µM, and 42 nM for human A1, A2A, A2B, A3 respectively). Shown to be centrally active following systemic administration and exhibits anti-convulsive effects. Also reported to inhibit adenylate cyclase activity in rat fat cell membrane (IC50 = 33 nM). Diminishes respiratory rhythm, reduces heart rate, and enhances the activity of KATP channels. Reduces norepinephrine release by about 50% in untreated and pertussis toxin treated hearts.
      FormWhite solid
      Intert gas (Yes/No) Packaged under inert gas
      CAS number37739-05-2
      Chemical formulaC₁₅H₂₀ClN₅O₄
      Structure formulaStructure formula
      Purity≥99% by HPLC
      SolubilityDMSO (100 mM) or H₂O (5 mM)
      Storage +2°C to +8°C
      Protect from light
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Toxicity Standard Handling
      ReferencesBurgdorf, C. et al. 2005. J Cardiovasc Pharmacol. 45, 1.
      Klotz, K. N., et al. 2000. Naunyn Schmiedebergs Arch Pharmacol. 362, 382.
      Mironov, S., et al. 1990. J Neurophysiol. 81, 1.
      Monopoli, A., et al. 1994.Arzneimittelforschung. 44, 1305.
      Concas, A., et al. 1993. J Pharmacol Exp Ther. 267, 844.
      Lohse, M. J., et al. 1988. Nauryn Schmiedebergs Arch Pharmacol. 337, 687.
      Coffin, V. L., et al. 1987. J Pharmacol Exp Ther. 241, 76.